Menu

CIRM Ups Translational Velocity

California’s stem cell agency unveiled a 5-year plan that includes starting 50 new clinical trials.

Dec 21, 2015
Bob Grant

WIKIMEDIA, CSIROThe California Institute for Regenerative Medicine (CIRM) announced its approval of an ambitious plan last week (December 17) that it will execute over the next five years, with the aim of getting more stem-cell therapies into the clinic or at least well on their way to commercialization.

The plan, which involves pushing more therapies into clinical trials at a quicker pace, will tap the remaining funds from the $3 billion California voters awarded the agency in 2004 by approving a ballot initiative known as proposition 71. “We have around $900 million left to work with, and we wanted a plan that used that money to produce the greatest possible impact for our patients,” Randy Mills, CIRM’s president and CEO, said in a statement. “We didn’t want something ‘good enough,’ we wanted something ‘transformational.’”

CIRM’s so-called “Stategic Plan” aims to start 50 new clinical trials of stem-cell therapies, aid in boosting the efficiency of the federal regulatory process for such products, and halve the amount of time it takes to go from discovery to clinical trials, among other goals. CIRM also plans to establish a center to assist researchers with navigating the regulatory approval process, and another to help researchers design and execute clinical trials.

“It’s ambitious, but then isn’t that what the people of California were when they approved Proposition 71,” Al Rowlett, a CIRM board member and CEO of the Turning Point mental health program in Sacramento, told California Stem Cell Report. “They wanted to create something that was going to change the face of medicine. That’s what we hope to do.”

The plan earmarks $620 million for clinical work and translational research, while $170 million will be devoted to basic research. Educational programs will get $50 million, and another $50 million will go towards infrastructure. CIRM also hopes to entice private partners, setting aside $75 million in matching funds to lure investors into partnerships on research that hasn’t yet secured such relationships.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!